Monitoring for life Senzime has developed a unique portfolio of products within the patient monitoring space. We’re just finalizing CE-approvals and global market launch will commence in 2017, says Lena Söderström, CEO Senzime About us TetraGraph » Clinisenz » OnZurf » About us Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients’ biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The Senzime AB (publ) share are listed on NASDAQ Stockholm First North. Short name: SEZI. Press releases 25 Sep 2017 Senzime submits 510 (k) application to the FDA Read more 18 Sep 2017 Senzime signs distribution agreement for the Swiss market Read more 15 Sep 2017 RESOLUTIONS AT SENZIME AB’S (PUBL) EXTRAORDINARY GENERAL MEETING Read more See all » News 29 Sep 2017 NEWS: Senzime reports from the Innovation Pavilion at The MedTech Conference Read more 09 Aug 2017 Senzime at the Innovation Pavilion Read more 08 Jun 2017 Interesting days at the Euroanesthesia 2017 meeting Read more See all » Are you interested? Contact us for more information Get contacted About us Home About us Investor Relations TetraGraph Clinisenz OnZurf Contact info@senzime.com +46 (0)18-51 56 40 Vallvägen 4A 756 51 Uppsala, Sweden Copyright 2017 Senzime info@senzime.com About Cookies Created with by wasabiweb CliniSenz, OnZurf, TetraGraph and TetraSens are trademarks owned by Senzime AB. INFO0005_v.1.0